FLUOROBOT the „Tata Nano of TB Diagnosis”

FLUOROBOT the „Tata Nano of TB Diagnosis”. An axample of Frugal Engineering. 
(Notes from the CEO)

A book review has struck my eyes a few weeks ago, in a medtech newsletter, that I receive regularly and find very useful. It appeared on the occasion of a book published recently by Peter Blair Henry: „Third World Lessons for First-World Medical Technology” 

The reason why I am glad that this topic hits the Medical Technology Industry (which in developed markets was rather „spoilt” earlier, with high budget institutional buyers) is because that is exactly what we followed in the Fluorobot development process

The author of this article – Norbert Sparrow, author of many thoughtful publications in medtech subjects – also quotes a panel discussion, with Carlos Ghosn among others, the „father” of the Frugal Engineering.

If you become hooked on about this engineering philosophy, as I have become since we restarted the Fluorobot project, you may find earlier publications very instructive, such as „The Importance of Frugal Engineering” by Vikas Sehgal, Kevin Dehoff and Gamesh Pamneer, which you may find in „Strategy-Business”  .

When we have restarted 4 years ago, we have spent more then a year just by optimizing the optical path – for one magnification, one set of optical elements, (objective, filters), maximal signal/noise ratio – instead of „stripping down” existing commercially available components, such as a piezo moving stage or a multipurpose microscope design. This is exactly what frugal engineering suggests, instead of cutting existing costs (multipurpose microscope) avoid needless costs in the first place We do not even claim Fluorobot is a microscope, it s a TB Screener – and in my mind it is the Tata Nano of TB Diagnosis. And to me, it is my conviction that this is not a synonym of „cheap, low-end” product, but that of clever engineering, and humble understanding of your market.

The basic philosophy of frugal engineering – doing more with less resources – has so strongly influenced project management and our developers’ team, that we knew if we do not succeed (come up with an affordable solution, good enough to carry out the automatic sputum smear screening watching our unit cost counter very closely) we will fail the whole project. And that is why we believe today, we have the only „Frugal TB Screener” in the world, instead of another experimental setup, seen at University Laboratories or elsewhere, which are going to find it difficult to be affordable in most of the cca. 80 thousand microscopy laboratories worldwide, most of which are in resource limited settings. They can of course solve the problem (it is no doubt possible with state of the art image processing of today) but keep such a long-awaited solution on this unmet market segment, out of reach of those laboratories, which are in greatest need, and can not even dream of being able to invest into more sensitive but expensive methods, such as Culture or Molecular Diagnostics.

Last but not least, besides our talented engineering teams, this has become possible by  listening to so many experts from the field. Input from senior microbiolgists from India to Brazil and organizations being active in delivering solutions to cure TB to the Third World, and the experts working for such organizations. When we first presented the functional model of our original design, we believed will be enabling us to come up with a TB Nano, we got the clear message:

if we can not hit the price barrier these laboratories are limited to, we will not have a product for this market, that will sell.

And to add a last comment, we are working with several Indian suppliers, to whom we never had to explain what we need. 

Donat Kiss

TB Epidemiology


•         With 8.8 Mi new cases annually and almost 1,5 Mi deaths, TB is still a leading mortality factor

•         TB is the leading killer of people with HIV

•         22 HBC (High Burden Country) countries account for 80% of the incidence

•         Annually over USD 1 Bi was spent on TB diagnostics in 2009, and the sum is increasing

•         TB drains 12 billion USD from the annual incomes of the poorest communities

•         Loss of productivity attributable to TB approaches 7% of GDP in some countries

•         In 2009 there were 9,7 million orphan children a a result of TB deaths


Nearly 4,000 people die from TB daily,

a curable disease in most cases !!


The Tireless Technician !